Amila Suraweera

Dr. Amila Suraweera is a Research Fellow and Visiting Fellow at the Queensland University of Technology (QUT), affiliated with the Faculty of Health and School of Biomedical Sciences. She holds a PhD in Molecular Biology and Biochemistry from the University of Queensland (2008) and a BSc (Honors) from the University of New South Wales (2002). Her research focuses on genomic stability, DNA repair mechanisms, and their implications in cancer biology, particularly lung cancer and drug discovery. Dr. Suraweera’s work explores pathways dysregulated in cancers, with a focus on proteins like COMMD4, Banf1, and Aldolase A, which influence DNA repair processes and therapeutic responses.

Her research interests include epigenetic therapy, targeted drug development, and the interplay between cellular metabolism and DNA repair. She has contributed to understanding the role of proteins like COMMD4 in lung cancer prognosis and therapy, as well as mechanisms regulating DNA double-strand break repair pathways. Dr. Suraweera has published extensively on topics such as epigenetic drugs in cancer therapy, protein complexes involved in DNA repair, and the metabolic regulation of repair processes.

Her articles highlight advancements in lung cancer treatment strategies, including targeting COMMD4-H2B complexes and leveraging Aldolase A for DNA repair modulation. Recent work emphasizes the clinical relevance of epigenetic mechanisms and drug sensitivity in cancer therapy. Dr. Suraweera collaborates with institutions like the MRC Laboratory of Molecular Biology and maintains affiliations with multiple research programs in cancer genomics and personalized health.

While no formal awards are listed, her contributions to cancer research are evident through her publications and collaborative projects. Her research has implications for developing novel therapeutic approaches and biomarkers in oncology.